Pdx Pharmaceuticals

Executive Summary

PDX Pharmaceuticals (DBA Raksa Therapeutics) is a preclinical-stage biopharmaceutical company leveraging its proprietary Pdx-NP™ silica-based nanoparticle platform to develop next-generation combination immunotherapies for cancer. The platform enables co-delivery of multiple therapeutic cargos, including siRNA, drugs, and immunotherapies, to enhance cancer-specific immunity. Founded as a spin-out from Oregon Health & Science University (OHSU) in 2015, the company has been advancing its pipeline through IND-enabling studies supported by funding from the National Cancer Institute (NCI). PDX focuses on addressing key limitations of current immunotherapies, such as low response rates and immune evasion, by precisely targeting tumor microenvironments. With a strong scientific foundation and government backing, the company is positioned to enter clinical development within the next 12–18 months. The company's primary near-term value inflection point is the completion of IND-enabling studies and submission of an IND application for its lead candidate. Success would pave the way for first-in-human clinical trials, potentially unlocking significant partnership and financing opportunities. PDX's technology has broad applicability across multiple cancer types, and its modular platform offers flexibility for future pipeline expansion. While still early-stage and unpartnered, the company benefits from NCI non-dilutive funding and a clear regulatory path. Key risks include preclinical efficacy and safety hurdles, as well as competitive pressure from other nanoparticle and immuno-oncology platforms. Overall, PDX represents a speculative but promising opportunity in targeted cancer immunotherapy.

Upcoming Catalysts (preview)

• Q3 2026IND Submission for Lead Nano-Immunotherapy Candidate60% success
• Q4 2026Award of Additional NCI Grant or SBIR Funding70% success
• Q1 2027Partnering or Licensing Deal for Pdx-NP Platform40% success